Healthcare Industry News: antibiotic
News Release - February 17, 2010
Lantheus Medical Imaging, Inc. Announces Appointment of Robert A. Spurr as Vice President, Sales and MarketingN. BILLERICA, Mass., Feb 17--(HSMN NewsFeed)--Lantheus Medical Imaging, Inc. announced today the appointment of Robert A. Spurr to the position of Vice President, Sales and Marketing. He joins Lantheus with more than 20 years of industry experience at Novartis Pharmaceuticals, Aventis Pharmaceuticals and most recently Ortho-McNeil®, a pharmaceuticals division of Johnson and Johnson, where he was Vice President Sales and Marketing, Institutional Franchise. The company also announced that David Mann will assume the newly formed position of Vice President, Operations and Professional Relations.
“Bob has a strong and distinguished track record in sales and marketing and he is a welcome addition to the Lantheus management team,” said Don Kiepert, President and CEO of Lantheus Medical Imaging. “His skills will be useful as we drive sales of our echocardiography contrast agent DEFINITY®, our recently launched MRA agent, ABLAVARTM, and our other important diagnostic agents. In particular, Bob’s experience in the managed care arena will enable us to better position our products in the evolving healthcare environment so that we can continue to provide cost-effective solutions for the diagnosis of disease for our customers and the patients they serve.”
“Molecular imaging diagnostics are key to more efficient and effective use of healthcare dollars, and Lantheus’ heritage of innovation and leadership in the industry, combined with its strong product portfolio and promising pipeline, presented me with a compelling opportunity to apply my skills at a company dedicated to being part of the solution to healthcare,” said Mr. Spurr.
Mr. Spurr was most recently Vice President Sales and Marketing, Institutional Franchise, at Ortho-McNeil Inc. While there, he led the hospital sales and marketing organization and successfully launched one of their antibiotic products. Earlier at Ortho-McNeil, he was Vice President, Strategic Business Group, North American Pharmaceuticals, where he established a fully integrated managed care organization that combined Janssen and Ortho-McNeil businesses and included responsibility for supply chain, customer marketing, account management, pricing and contracting. Prior to that, Mr. Spurr held positions of increasing responsibility at Aventis Pharmaceuticals and Novartis Pharmaceuticals. He received a B.S. degree from Keene State College and holds an M.B.A. from Rutgers.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve treatment of human disease. The company’s proven success in discovering, developing and marketing innovative medical imaging agents provides a solid platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. The company is home to leading cardiac imaging brands, including Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, and TechneLite® (Technetium Tc99m Generator). The company is also now home to ABLAVAR™ (gadofosveset trisodium), a first-in-class blood pool contrast agent for magnetic resonance angiography. Lantheus has more than 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
Source: Lantheus Medical Imaging
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.